Hepatitis C Drug Market

Hepatitis C Drug Market - Global Industry Assessment & Forecast

Healthcare

# Pages:

144

Base Year:

2022

Aug - 2023

Format:

Report Code:

VMR-2239

Segments Covered

By Product Type NS5A Inhibitor (Protease Inhibitors), Fixed-dose Combination, Other Products
By Disease Type Acute Hepatitis C, Chronic Hepatitis C
By Distribution Channel Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Other Distribution Channels
By Region North America, Europe, Asia Pacific, Latin America, Middle East & Africa

Standard License

$ 4299 USD

Multi User License

$ 6599 USD

Enterprise License

$ 6999 USD

Snapshot

Base Year:	2022
Forecast Years:	2023 - 2030
Historical Years:	2017 - 2021
Revenue 2022:	USD 21.9 Billion
Revenue 2030:	USD 56.5 Billion
Revenue CAGR (2023 - 2030):	14.5%
Fastest Growing Region (2023 - 2030)	Asia Pacific
Largest Region (2022):	North America

Customization Offered

Cross-segment Market Size and Analysis for Mentioned Segments
Additional Company Profiles (Upto 5 With No Cost)
Additional Countries (Apart From Mentioned Countries)
Country/Region-specific Report
Go To Market Strategy
Region Specific Market Dynamics
Region Level Market Share
Import Export Analysis
Production Analysis
Others Request Customization Speak To Analyst

Executive Dashboard
1. Strategic Imperatives
Premium Insights
1. Top 3 Trends to Watch
2. Demand and Supply Trends
3. Top 3 Strategies Followed by Major Players
4. Top 3 Predictions by Vantage Market Research
5. Top Investment Pockets
6. Insights from Primary Respondents
Global Hepatitis C Drug Market - Segment Analysis
1. Overview
2. Global Hepatitis C Drug Market, 2016 - 2028 (USD Million)
3. Global Hepatitis C Drug Market - by Product Type
  1. By NS5A Inhibitor (Protease Inhibitors)
  2. By Fixed-dose Combination
  3. By Other Products
4. Global Hepatitis C Drug Market - by Disease Type
  1. By Acute Hepatitis C
  2. By Chronic Hepatitis C
5. Global Hepatitis C Drug Market - by Distribution Channel
  1. By Hospital Pharmacies
  2. By Retail Pharmacies
  3. By Online Pharmacies
  4. By Other Distribution Channels
6. Global Hepatitis C Drug Market - by region
  1. North America
  2. Europe
  3. Asia Pacific
  4. Latin America
  5. Middle East & Africa
7. Market comparative analysis
North America Hepatitis C Drug Market - Segment Analysis
1. Overview
2. North America Hepatitis C Drug Market, 2016 - 2028 (USD Million)
3. North America Hepatitis C Drug Market, by Product Type
  1. By NS5A Inhibitor (Protease Inhibitors)
  2. By Fixed-dose Combination
  3. By Other Products
4. North America Hepatitis C Drug Market, by Disease Type
  1. By Acute Hepatitis C
  2. By Chronic Hepatitis C
5. North America Hepatitis C Drug Market, by Distribution Channel
  1. By Hospital Pharmacies
  2. By Retail Pharmacies
  3. By Online Pharmacies
  4. By Other Distribution Channels
6. North America Hepatitis C Drug Market, by Country
  1. U.S.
    1. U.S. Hepatitis C Drug Market, By Product Type
      1. By NS5A Inhibitor (Protease Inhibitors)
      2. By Fixed-dose Combination
      3. By Other Products
    2. U.S. Hepatitis C Drug Market, By Disease Type
      1. By Acute Hepatitis C
      2. By Chronic Hepatitis C
    3. U.S. Hepatitis C Drug Market, By Distribution Channel
      1. By Hospital Pharmacies
      2. By Retail Pharmacies
      3. By Online Pharmacies
      4. By Other Distribution Channels
  2. Canada
    1. Canada Hepatitis C Drug Market, By Product Type
      1. By NS5A Inhibitor (Protease Inhibitors)
      2. By Fixed-dose Combination
      3. By Other Products
    2. Canada Hepatitis C Drug Market, By Disease Type
      1. By Acute Hepatitis C
      2. By Chronic Hepatitis C
    3. Canada Hepatitis C Drug Market, By Distribution Channel
      1. By Hospital Pharmacies
      2. By Retail Pharmacies
      3. By Online Pharmacies
      4. By Other Distribution Channels
  3. Mexico
    1. Mexico Hepatitis C Drug Market, By Product Type
      1. By NS5A Inhibitor (Protease Inhibitors)
      2. By Fixed-dose Combination
      3. By Other Products
    2. Mexico Hepatitis C Drug Market, By Disease Type
      1. By Acute Hepatitis C
      2. By Chronic Hepatitis C
    3. Mexico Hepatitis C Drug Market, By Distribution Channel
      1. By Hospital Pharmacies
      2. By Retail Pharmacies
      3. By Online Pharmacies
      4. By Other Distribution Channels
Europe Hepatitis C Drug Market - Segment Analysis
1. Overview
2. Europe Hepatitis C Drug Market, 2016 - 2028 (USD Million)
3. Europe Hepatitis C Drug Market, by Product Type
  1. By NS5A Inhibitor (Protease Inhibitors)
  2. By Fixed-dose Combination
  3. By Other Products
4. Europe Hepatitis C Drug Market, by Disease Type
  1. By Acute Hepatitis C
  2. By Chronic Hepatitis C
5. Europe Hepatitis C Drug Market, by Distribution Channel
  1. By Hospital Pharmacies
  2. By Retail Pharmacies
  3. By Online Pharmacies
  4. By Other Distribution Channels
6. Europe Hepatitis C Drug Market, by Country
  1. Germany
    1. Germany Hepatitis C Drug Market, By Product Type
      1. By NS5A Inhibitor (Protease Inhibitors)
      2. By Fixed-dose Combination
      3. By Other Products
    2. Germany Hepatitis C Drug Market, By Disease Type
      1. By Acute Hepatitis C
      2. By Chronic Hepatitis C
    3. Germany Hepatitis C Drug Market, By Distribution Channel
      1. By Hospital Pharmacies
      2. By Retail Pharmacies
      3. By Online Pharmacies
      4. By Other Distribution Channels
  2. UK
    1. UK Market, By Product Type
      1. By NS5A Inhibitor (Protease Inhibitors)
      2. By Fixed-dose Combination
      3. By Other Products
    2. UK Market, By Disease Type
      1. By Acute Hepatitis C
      2. By Chronic Hepatitis C
    3. UK Market, By Distribution Channel
      1. By Hospital Pharmacies
      2. By Retail Pharmacies
      3. By Online Pharmacies
      4. By Other Distribution Channels
  3. France
    1. France Hepatitis C Drug Market, By Product Type
      1. By NS5A Inhibitor (Protease Inhibitors)
      2. By Fixed-dose Combination
      3. By Other Products
    2. France Hepatitis C Drug Market, By Disease Type
      1. By Acute Hepatitis C
      2. By Chronic Hepatitis C
    3. France Hepatitis C Drug Market, By Distribution Channel
      1. By Hospital Pharmacies
      2. By Retail Pharmacies
      3. By Online Pharmacies
      4. By Other Distribution Channels
  4. Spain
    1. Spain Hepatitis C Drug Market, By Product Type
      1. By NS5A Inhibitor (Protease Inhibitors)
      2. By Fixed-dose Combination
      3. By Other Products
    2. Spain Hepatitis C Drug Market, By Disease Type
      1. By Acute Hepatitis C
      2. By Chronic Hepatitis C
    3. Spain Hepatitis C Drug Market, By Distribution Channel
      1. By Hospital Pharmacies
      2. By Retail Pharmacies
      3. By Online Pharmacies
      4. By Other Distribution Channels
  5. Italy
    1. Italy Hepatitis C Drug Market, By Product Type
      1. By NS5A Inhibitor (Protease Inhibitors)
      2. By Fixed-dose Combination
      3. By Other Products
    2. Italy Hepatitis C Drug Market, By Disease Type
      1. By Acute Hepatitis C
      2. By Chronic Hepatitis C
    3. Italy Hepatitis C Drug Market, By Distribution Channel
      1. By Hospital Pharmacies
      2. By Retail Pharmacies
      3. By Online Pharmacies
      4. By Other Distribution Channels
  6. BENELUX
    1. BENELUX Hepatitis C Drug Market, By Product Type
      1. By NS5A Inhibitor (Protease Inhibitors)
      2. By Fixed-dose Combination
      3. By Other Products
    2. BENELUX Hepatitis C Drug Market, By Disease Type
      1. By Acute Hepatitis C
      2. By Chronic Hepatitis C
    3. BENELUX Hepatitis C Drug Market, By Distribution Channel
      1. By Hospital Pharmacies
      2. By Retail Pharmacies
      3. By Online Pharmacies
      4. By Other Distribution Channels
  7. Rest of Europe
    1. Rest Of Europe Hepatitis C Drug Market, By Product Type
      1. By NS5A Inhibitor (Protease Inhibitors)
      2. By Fixed-dose Combination
      3. By Other Products
    2. Rest Of Europe Hepatitis C Drug Market, By Disease Type
      1. By Acute Hepatitis C
      2. By Chronic Hepatitis C
    3. Rest Of Europe Hepatitis C Drug Market, By Distribution Channel
      1. By Hospital Pharmacies
      2. By Retail Pharmacies
      3. By Online Pharmacies
      4. By Other Distribution Channels
Asia Pacific Hepatitis C Drug Market - Segment Analysis
1. Overview
2. Asia Pacific Hepatitis C Drug Market, 2016 - 2028 (USD Million)
3. Asia Pacific Hepatitis C Drug Market, by Product Type
  1. By NS5A Inhibitor (Protease Inhibitors)
  2. By Fixed-dose Combination
  3. By Other Products
4. Asia Pacific Hepatitis C Drug Market, by Disease Type
  1. By Acute Hepatitis C
  2. By Chronic Hepatitis C
5. Asia Pacific Hepatitis C Drug Market, by Distribution Channel
  1. By Hospital Pharmacies
  2. By Retail Pharmacies
  3. By Online Pharmacies
  4. By Other Distribution Channels
6. Asia Pacific Hepatitis C Drug Market, by Country
  1. China
    1. China Hepatitis C Drug Market, By Product Type
      1. By NS5A Inhibitor (Protease Inhibitors)
      2. By Fixed-dose Combination
      3. By Other Products
    2. China Hepatitis C Drug Market, By Disease Type
      1. By Acute Hepatitis C
      2. By Chronic Hepatitis C
    3. China Hepatitis C Drug Market, By Distribution Channel
      1. By Hospital Pharmacies
      2. By Retail Pharmacies
      3. By Online Pharmacies
      4. By Other Distribution Channels
  2. Japan
    1. Japan Hepatitis C Drug Market, By Product Type
      1. By NS5A Inhibitor (Protease Inhibitors)
      2. By Fixed-dose Combination
      3. By Other Products
    2. Japan Hepatitis C Drug Market, By Disease Type
      1. By Acute Hepatitis C
      2. By Chronic Hepatitis C
    3. Japan Hepatitis C Drug Market, By Distribution Channel
      1. By Hospital Pharmacies
      2. By Retail Pharmacies
      3. By Online Pharmacies
      4. By Other Distribution Channels
  3. India
    1. India Hepatitis C Drug Market, By Product Type
      1. By NS5A Inhibitor (Protease Inhibitors)
      2. By Fixed-dose Combination
      3. By Other Products
    2. India Hepatitis C Drug Market, By Disease Type
      1. By Acute Hepatitis C
      2. By Chronic Hepatitis C
    3. India Hepatitis C Drug Market, By Distribution Channel
      1. By Hospital Pharmacies
      2. By Retail Pharmacies
      3. By Online Pharmacies
      4. By Other Distribution Channels
  4. South Korea
    1. South Korea Hepatitis C Drug Market, By Product Type
      1. By NS5A Inhibitor (Protease Inhibitors)
      2. By Fixed-dose Combination
      3. By Other Products
    2. South Korea Hepatitis C Drug Market, By Disease Type
      1. By Acute Hepatitis C
      2. By Chronic Hepatitis C
    3. South Korea Hepatitis C Drug Market, By Distribution Channel
      1. By Hospital Pharmacies
      2. By Retail Pharmacies
      3. By Online Pharmacies
      4. By Other Distribution Channels
  5. South East Asia
    1. South East Asia Hepatitis C Drug Market, By Product Type
      1. By NS5A Inhibitor (Protease Inhibitors)
      2. By Fixed-dose Combination
      3. By Other Products
    2. South East Asia Hepatitis C Drug Market, By Disease Type
      1. By Acute Hepatitis C
      2. By Chronic Hepatitis C
    3. South East Asia Hepatitis C Drug Market, By Distribution Channel
      1. By Hospital Pharmacies
      2. By Retail Pharmacies
      3. By Online Pharmacies
      4. By Other Distribution Channels
  6. Rest of Asia Pacific
    1. Rest of Asia Pacific Hepatitis C Drug Market, By Product Type
      1. By NS5A Inhibitor (Protease Inhibitors)
      2. By Fixed-dose Combination
      3. By Other Products
    2. Rest of Asia Pacific Hepatitis C Drug Market, By Disease Type
      1. By Acute Hepatitis C
      2. By Chronic Hepatitis C
    3. Rest of Asia Pacific Hepatitis C Drug Market, By Distribution Channel
      1. By Hospital Pharmacies
      2. By Retail Pharmacies
      3. By Online Pharmacies
      4. By Other Distribution Channels
Latin America Hepatitis C Drug Market - Segment Analysis
1. Overview
2. Latin America Hepatitis C Drug Market, 2016 - 2028 (USD Million)
3. Latin America Hepatitis C Drug Market, by Product Type
  1. By NS5A Inhibitor (Protease Inhibitors)
  2. By Fixed-dose Combination
  3. By Other Products
4. Latin America Hepatitis C Drug Market, by Disease Type
  1. By Acute Hepatitis C
  2. By Chronic Hepatitis C
5. Latin America Hepatitis C Drug Market, by Distribution Channel
  1. By Hospital Pharmacies
  2. By Retail Pharmacies
  3. By Online Pharmacies
  4. By Other Distribution Channels
6. Latin America Hepatitis C Drug Market, by Country
  1. Brazil
    1. Brazil Hepatitis C Drug Market, By Product Type
      1. By NS5A Inhibitor (Protease Inhibitors)
      2. By Fixed-dose Combination
      3. By Other Products
    2. Brazil Hepatitis C Drug Market, By Disease Type
      1. By Acute Hepatitis C
      2. By Chronic Hepatitis C
    3. Brazil Hepatitis C Drug Market, By Distribution Channel
      1. By Hospital Pharmacies
      2. By Retail Pharmacies
      3. By Online Pharmacies
      4. By Other Distribution Channels
  2. Argentina
    1. Argentina Hepatitis C Drug Market, By Product Type
      1. By NS5A Inhibitor (Protease Inhibitors)
      2. By Fixed-dose Combination
      3. By Other Products
    2. Argentina Hepatitis C Drug Market, By Disease Type
      1. By Acute Hepatitis C
      2. By Chronic Hepatitis C
    3. Argentina Hepatitis C Drug Market, By Distribution Channel
      1. By Hospital Pharmacies
      2. By Retail Pharmacies
      3. By Online Pharmacies
      4. By Other Distribution Channels
  3. Rest of Latin America
    1. Rest of Latin America Hepatitis C Drug Market, By Product Type
      1. By NS5A Inhibitor (Protease Inhibitors)
      2. By Fixed-dose Combination
      3. By Other Products
    2. Rest of Latin America Hepatitis C Drug Market, By Disease Type
      1. By Acute Hepatitis C
      2. By Chronic Hepatitis C
    3. Rest of Latin America Hepatitis C Drug Market, By Distribution Channel
      1. By Hospital Pharmacies
      2. By Retail Pharmacies
      3. By Online Pharmacies
      4. By Other Distribution Channels
Middle East & Africa Hepatitis C Drug Market - Segment Analysis
1. Overview
2. Middle East & Africa Hepatitis C Drug Market, 2016 - 2028 (USD Million)
3. Middle East & Africa Hepatitis C Drug Market, by Product Type
  1. By NS5A Inhibitor (Protease Inhibitors)
  2. By Fixed-dose Combination
  3. By Other Products
4. Middle East & Africa Hepatitis C Drug Market, by Disease Type
  1. By Acute Hepatitis C
  2. By Chronic Hepatitis C
5. Middle East & Africa Hepatitis C Drug Market, by Distribution Channel
  1. By Hospital Pharmacies
  2. By Retail Pharmacies
  3. By Online Pharmacies
  4. By Other Distribution Channels
6. Middle East & Africa Hepatitis C Drug Market, by Country
  1. GCC Countries
    1. GCC Countries Hepatitis C Drug Market, By Product Type
      1. By NS5A Inhibitor (Protease Inhibitors)
      2. By Fixed-dose Combination
      3. By Other Products
    2. GCC Countries Hepatitis C Drug Market, By Disease Type
      1. By Acute Hepatitis C
      2. By Chronic Hepatitis C
    3. GCC Countries Hepatitis C Drug Market, By Distribution Channel
      1. By Hospital Pharmacies
      2. By Retail Pharmacies
      3. By Online Pharmacies
      4. By Other Distribution Channels
  2. South Africa
    1. South Africa Hepatitis C Drug Market, By Product Type
      1. By NS5A Inhibitor (Protease Inhibitors)
      2. By Fixed-dose Combination
      3. By Other Products
    2. South Africa Hepatitis C Drug Market, By Disease Type
      1. By Acute Hepatitis C
      2. By Chronic Hepatitis C
    3. South Africa Hepatitis C Drug Market, By Distribution Channel
      1. By Hospital Pharmacies
      2. By Retail Pharmacies
      3. By Online Pharmacies
      4. By Other Distribution Channels
  3. Rest of Middle East & Africa
    1. Rest of Middle East & Africa Hepatitis C Drug Market, By Product Type
      1. By NS5A Inhibitor (Protease Inhibitors)
      2. By Fixed-dose Combination
      3. By Other Products
    2. Rest of Middle East & Africa Hepatitis C Drug Market, By Disease Type
      1. By Acute Hepatitis C
      2. By Chronic Hepatitis C
    3. Rest of Middle East & Africa Hepatitis C Drug Market, By Distribution Channel
      1. By Hospital Pharmacies
      2. By Retail Pharmacies
      3. By Online Pharmacies
      4. By Other Distribution Channels
Key Market Dynamics
1. Introduction
2. Market Drivers
3. Market Restraints
4. Market Opportunities
5. Porter's Five Forces Analysis
6. PEST Analysis
7. Regulatory Landscape
8. Technology Landscape
9. Regional Market Trends
COVID 19 Impact Analysis
1. Key strategies undertaken by companies to tackle COVID-19
2. Short term dynamics
3. Long term dynamics
Marketing Stratagy Analysis
1. Marketing Channel
2. Direct Marketing
3. Indirect Marketing
4. Marketing Channel Development Trends
Competative Landscape
1. Competition Matrix - 2021
2. Company Market Share Analysis - 2021
3. Key Company Activities, 2018 - 2021
4. Strategic Developments - Heat Map Analysis
5. Company Offering Evaluation
6. Company Regional Presence Evaluation
Company Profiles
1. AbbVie Inc. (U.S.)
2. Gilead Sciences Inc. (U.S.)
3. Bristol-Myers Squibb Company (U.S.)
4. Janssen Pharmaceuticals Inc. (Belgium)
5. Merck Sharp & Dohme Corp. (U.S.)
6. F. Hoffmann-La Roche Ltd. (Switzerland)
7. Vertex Pharmaceuticals Inc. (U.S.)
8. Novartis AG (Switzerland)
9. Pfizer Inc. (U.S.)
10. Roche Holding AG (Switzerland)
11. GlaxoSmithKline PLC (UK)
12. Mylan N.V. (U.S.)
13. Eli Lilly and Company (U.S.)
14. Bayer AG (Germany)
15. AstraZeneca PLC (UK)
16. Sanofi S.A. (France)
17. Teva Pharmaceutical Industries Ltd. (Israel)
Key Primary Respondents - VERBATIM
Discussion Guide
Customization Offered
Annexure
List of Figures
List of Tables
List of Abbreviations

Vantage Market Research | 11-Aug-2023

Hepatitis C Drug Market to Reach Valuation of USD 56.5 Billion by 2030 – Rapidly Growing Awareness about Hepatitis C Drugs Drives the Market

FAQ

Frequently Asked Question

What is the global demand for Hepatitis C Drug in terms of revenue?

The global Hepatitis C Drug valued at USD 21.9 Billion in 2022 and is expected to reach USD 56.5 Billion in 2030 growing at a CAGR of 14.5%.

Which are the prominent players in the market?

The prominent players in the market are AbbVie Inc. (U.S.), Gilead Sciences Inc. (U.S.), Bristol-Myers Squibb Company (U.S.), Janssen Pharmaceuticals Inc. (Belgium), Merck Sharp & Dohme Corp. (U.S.), F. Hoffmann-La Roche Ltd. (Switzerland), Vertex Pharmaceuticals Inc. (U.S.), Novartis AG (Switzerland), Pfizer Inc. (U.S.), Roche Holding AG (Switzerland), GlaxoSmithKline PLC (UK), Mylan N.V. (U.S.), Eli Lilly and Company (U.S.), Bayer AG (Germany), AstraZeneca PLC (UK), Sanofi S.A. (France), Teva Pharmaceutical Industries Ltd. (Israel).

At what CAGR is the market projected to grow within the forecast period?

The market is project to grow at a CAGR of 14.5% between 2023 and 2030.

What are the driving factors fueling the growth of the market.

The driving factors of the Hepatitis C Drug include
- “Increased Awareness and Innovation of New Drugs is likely to direct the Hepatitis C Treatment Market.”

Which region accounted for the largest share in the market?

North America was the leading regional segment of the Hepatitis C Drug in 2022.

Hepatitis C Drug Market

Hepatitis C Drug Market - Global Industry Assessment & Forecast

Healthcare

Segments Covered

Snapshot

Customization Offered

FAQ

Frequently Asked Question

What is the global demand for Hepatitis C Drug in terms of revenue?

Which are the prominent players in the market?

At what CAGR is the market projected to grow within the forecast period?

What are the driving factors fueling the growth of the market.

Which region accounted for the largest share in the market?

Quick Links

For Buying Inquiry

Hepatitis C Drug Market

Hepatitis C Drug Market - Global Industry Assessment & Forecast

Healthcare

Segments Covered

Snapshot

Customization Offered

FAQ

Frequently Asked Question

What is the global demand for Hepatitis C Drug in terms of revenue?

Which are the prominent players in the market?

At what CAGR is the market projected to grow within the forecast period?

What are the driving factors fueling the growth of the market.

Which region accounted for the largest share in the market?

Related Reports

Request Sample Report for Hepatitis C Drug Market

Vantage Point Interactive Dashboard